Sponsors (14)
The bill increases point-of-care information and creates a dedicated hotline for mifepristone, but it risks spreading misleading medical claims, delaying evidence-based care, imposing regulatory burdens on providers, and adding taxpayer costs.
Women would have access to a 24/7 hotline for immediate guidance about mifepristone use and questions.
Patients and providers (especially women and healthcare workers) would receive additional mandated product information at the point of dispensing through new labeling.
Healthcare workers and contractors could gain jobs if the hotline and related programs are funded by HHS administration or grants.
Women and their clinicians could face delays or deterrence of timely, evidence-based abortion or follow-up care because label warnings and restricted hotline referrals may push information or referrals that prolong decision-making or access.
Women seeking care could be exposed to misleading or false claims about 'abortion pill reversal,' which may influence their treatment decisions and clinical outcomes.
Hospitals, manufacturers, and healthcare providers could face legal and regulatory conflicts and higher compliance costs because the requirement compels FDA/manufacturers to include a medically contested claim on labeling.
Based on analysis of 2 sections of legislative text.
Introduced January 28, 2025 by Mary E. Miller · Last progress January 28, 2025
Requires a new warning label on the abortion drug mifepristone saying natural progesterone can counteract the drug and may increase chances of fetal survival, and directs readers to a toll-free hotline. Also directs the federal health secretary to create or maintain a 24/7 hotline that refers callers only to providers offering “abortion pill reversal” (APR) services. The label requirement takes effect six months after enactment. The hotline must be provided directly or via grant or contract and is limited to referring callers to APR providers; the bill does not specify funding levels for operating the hotline.